Report
Martial Descoutures ...
  • Oussema Denguir

AstraZeneca : Phase III trial of COVID-19 vaccine halted following adverse effects

>Vaccine trial put on hold after a severe adverse effect - As reported by the medical news website STAT overnight, AstraZeneca has confirmed that phase III trials of its COVID-19 vaccine have been halted following a suspected serious adverse effect. According to the NY Times, it is a rare instance of inflammation of the spinal cord (transverse myelitis) in the UK. This type of inflammation may be caused by a viral infection; note that AZN's vaccine is based on a viral...
Underlying
AstraZeneca PLC

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch